|
68 Companies |
|
79 Products |
|
79 Products |
|
71 Mechanisms of Action |
|
0 Trials |
|
484 News |
|
| «12345678910» |
- |||| Stelara (ustekinumab) / J&J
Trial completion: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Feb 19, 2015
P2, N=79, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed
- || lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Trial primary completion date: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Feb 15, 2015
P2, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Dec 2016
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2017 --> Dec 2016 Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Aug 2015 --> Mar 2015
- | Trial completion, Trial primary completion date: Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD) (clinicaltrials.gov) - Feb 2, 2015
P1, N=30, Completed, Sponsor: LEO Pharma
Trial primary completion date: Aug 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Feb 2015 --> Jul 2015
- |||| Eucrisa (crisaborole) / Pfizer
Trial primary completion date: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P3, N=750, Recruiting, Sponsor: Anacor Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P2 trial: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2015
P2, N=184, Not yet recruiting, Sponsor: MedImmune LLC
- | rosiptor (AQX-1125) / Neoleukin Therap
Enrollment open: KINSHIP: Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (clinicaltrials.gov) - Jan 23, 2015
P2, N=50, Recruiting, Sponsor: Aquinox Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- Clinical: The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=24, Not yet recruiting, Sponsor: Seoul National University Hospital
- Clinical: A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants (clinicaltrials.gov) - Jan 22, 2015
P0, N=44, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Trial completion, Trial primary completion date: Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream (clinicaltrials.gov) - Jan 22, 2015
P1, N=23, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Nov 2014
- ||||| lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
New P2 trial: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 18, 2015
P2, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- fluticasone / Generic mfg.
Enrollment change, Trial termination: Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children (clinicaltrials.gov) - Jan 9, 2015
P3, N=54, Terminated, Sponsor: Elena Rubio Gomis
Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Nov 2014 N=100 --> 54 | Recruiting --> Terminated; Patient recruitment is very slow, economic grant has ended and the number of patients is enough according to sample size (22 children/ arm).
- ||| KHK4577 / Kyowa Kirin
Enrollment closed: Phase 2 Study of KHK4577 (clinicaltrials.gov) - Jan 9, 2015
P2, N=90, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
N=100 --> 54 | Recruiting --> Terminated; Patient recruitment is very slow, economic grant has ended and the number of patients is enough according to sample size (22 children/ arm). Recruiting --> Active, not recruiting
- | difamilast (MM36) / Otsuka, Medimetriks
New P1 trial: A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects (clinicaltrials.gov) - Jan 8, 2015
P1, N=32, Recruiting, Sponsor: Otsuka Pharmaceutical Co., Ltd.
- || tradipitant (VLY-686) / Vanda
Trial primary completion date: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Jan 6, 2015
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Mar 2015
- || MEDI 4212 / AstraZeneca
Enrollment change: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL (clinicaltrials.gov) - Dec 30, 2014
P1, N=295, Completed, Sponsor: MedImmune LLC
Trial primary completion date: Aug 2014 --> Mar 2015 N=86 --> 295
- Enrollment open: Cognitive Behavior Therapy for Atopic Dermatitis (clinicaltrials.gov) - Dec 27, 2014
P=N/A, N=25, Recruiting, Sponsor: Karolinska Institutet
N=86 --> 295 Not yet recruiting --> Recruiting
- | rosiptor (AQX-1125) / Neoleukin Therap
New P2 trial: KINSHIP: Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (clinicaltrials.gov) - Dec 25, 2014
P2, N=50, Not yet recruiting, Sponsor: Aquinox Pharmaceuticals, Inc.
- |||||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment open, Monotherapy: SOLO 1: Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 24, 2014
P3, N=600, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis (clinicaltrials.gov) - Dec 19, 2014
P4, N=0, Withdrawn, Sponsor: Trima, Israel Pharmaceutical Products
Not yet recruiting --> Recruiting N=60 --> 0 | Not yet recruiting --> Withdrawn
- triamcinolone acetonide topical / Generic mfg.
Biomarker, New P4 trial, IO biomarker, Biopsy: GNE-AD: A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (clinicaltrials.gov) - Dec 16, 2014
P4, N=15, Recruiting, Sponsor: University of California, San Francisco
- Trial completion, Enrollment change, Trial primary completion date, IO biomarker: 2ndDermisII: Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis (clinicaltrials.gov) - Dec 10, 2014
P2, N=78, Completed, Sponsor: Universidade do Porto
N=60 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=100 --> 78 | Trial primary completion date: Dec 2012 --> Jun 2012
- ||| Trial completion: Chronic Hand Eczema - Self-management and Prognosis (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=306, Completed, Sponsor: University Hospital, Gentofte, Copenhagen
Active, not recruiting --> Completed | N=100 --> 78 | Trial primary completion date: Dec 2012 --> Jun 2012 Recruiting --> Completed
- Head-to-Head: CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: Northwestern University
- Enrollment open: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis (clinicaltrials.gov) - Nov 18, 2014
P2, N=0, Withdrawn, Sponsor: Tecno Sun SRL
Not yet recruiting --> Recruiting N=64 --> 0 | Recruiting --> Withdrawn
- MK-8226 / Merck (MSD)
Trial termination: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) - Nov 17, 2014
P1, N=64, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=64 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Terminated; The study was prematurely stopped due to business reasons.
- Clinical: Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=40, Recruiting, Sponsor: Rutgers, The State University of New Jersey
- | pimecrolimus topical / Generic mfg.
Trial completion: A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Nov 13, 2014
P1, N=30, Completed, Sponsor: LEO Pharma
Active, not recruiting --> Terminated; The study was prematurely stopped due to business reasons. Active, not recruiting --> Completed
- ||| fevipiprant (QAW039) / Novartis
Enrollment closed: Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - Nov 5, 2014
P2, N=103, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- tacrolimus topical / Generic mfg.
Enrollment open, Trial primary completion date, Adherence: Protopic Adherence and Efficacy in Korean Eczema Patient (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=50, Recruiting, Sponsor: Pusan National University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2016
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
New P3 trial, Monotherapy: SOLO 1: Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 30, 2014
P3, N=600, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Enrollment closed, IO biomarker: VIDATOPIC: Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Pontificia Universidad Catolica de Chile
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Ohio State University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014
- || MK-8226 / Merck (MSD)
Enrollment change: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) - Oct 20, 2014
P1, N=64, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014 N=170 --> 64
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
New P3 trial: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 10, 2014
P3, N=700, Recruiting, Sponsor: Regeneron Pharmaceuticals
- Clinical: Randomized Controlled Trial of an Eczema Care Plan (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: Children's Hospital Boston
- Enrollment open, Trial primary completion date: Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=126, Recruiting, Sponsor: Nestlé
N=170 --> 64 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jul 2017
- pimecrolimus topical / Generic mfg.
Trial completion, Preclinical, Biopsy: Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis (clinicaltrials.gov) - Sep 28, 2014
P4, N=28, Completed, Sponsor: National Jewish Health
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jul 2017 Not yet recruiting --> Completed
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Sep 22, 2014
P2, N=69, Completed, Sponsor: Pfizer
Not yet recruiting --> Completed Recruiting --> Completed
- |||| tacrolimus topical / Generic mfg.
Trial completion: A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis (clinicaltrials.gov) - Sep 17, 2014
P4, N=410, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Completed No longer recruiting --> Completed
- |||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Trial completion: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Sep 16, 2014
P2, N=380, Completed, Sponsor: Regeneron Pharmaceuticals
No longer recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: 0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis (clinicaltrials.gov) - Sep 16, 2014
P1, N=60, Recruiting, Sponsor: Makati Medical Center
- ||| Trial completion: Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=160, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment closed: COPES: Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=58, Active, not recruiting, Sponsor: Hyphens Pharma Pte Ltd
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Exploratory Study of Natural Killer Cells in Human Skin (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=28, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 28
- || BMS-981164 / BMS
Trial primary completion date: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis (clinicaltrials.gov) - Aug 29, 2014
P1, N=88, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=100 --> 28 Trial primary completion date: Jan 2015 --> Jun 2015
- cyclosporin A microemulsion / Generic mfg.
Clinical: Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=20, Completed, Sponsor: University of Aarhus